002262 2025-004

Pre-A

1 NeuroThree Therapeutics, Inc.

2
350 5

3

1

350 5 A
57*

2

2025 3 5
5
5 A

3

U 9 µ .

3 T 9M FU NH .SH

3 T9M 9M FU NH .SH MSL1 N

3 T9M 9M FU NH .SH

5 4 T , FSI 5F NQNTS - NGNH F F 7 TFI , FSI
(F RFS 0

* RU I (TRUFS

MSL1 N

N73 0(36 39
39 18
(38
0(36

MSL1N

5 0 S SI “0 ”
82 . -TQNSL1RNI -82 -TQNSL1RNI

MSL1N			
*845			

5

57*

5

3 T9M 9M FU NH .SH

3 T 9M FU NH .SH

5 NeuroThree Therapeutics, Inc. MSL1 N

6

1.01

1,250 Pre-A 350

1.02

15

ODI 5

2.01

2.02

(i)

(ii)

10

B

3.01

3.03

a (i) 100% (ii)

100% (iii)

100% 3.03(a)

b

c

3.04

(i)

(ii)

3.05

a

b

1933

4.01

4.03

5.01

5.02

5.04 ROFN

a

H. Lundbeck A/S 2023 4 20
1
[N3T040245]

7 4 3
7 4 3

b ROFN 30
ROFN
90 7 4 3

c ROFN
ROFN
ROFN 60 ROFN
ROFN

6.01

6.03

6.04

(i)

(ii)

6.05

6.06

6.07

6.08

7.01

7.02

7.03

7.04

7.05

(i)

(ii) (iii)

(iv)

8.01

a

(i)

(ii)

8.02

(i)

(ii) 8.01 8.02

8.01 8.02

8.03

8.04

8.05

8.06

8.08

8.09

8.10

8.14

8.16

a

30 8.16(b)

b (a)

- 0 . (

HKIAC (b)

8.18

(i) 12

(ii) (iii) (a) 12

(b)

15

1

2

1 2025 3 5

2

3

4 5 -A

5

2025 3 5